Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact email@example.com.
SOURCE Decision Resources Group
Immune Checkpoint Inhibitors Will Hold an Impressive 85 Percent Market Share, According to Findings from Decision Resources Group
BURLINGTON, Mass., June 30, 2014 /PRNewswire/ -- Decision Resources Group finds that the immunotherapy market will experience considerable growth through 2022, increasing from $1.1 billion in 2012 to nearly $9 billion in 2022 (corresponding to 23.8 percent annual growth) in the United States, France, Germany, Italy, Spain, United Kingdom and Japan. This impressive growth will be driven by the expected market entry of nine novel immunotherapies-including four novel immune checkpoint inhibitors and five novel therapeutic vaccines-in new oncology indications and/or patient populations. Taken together, Bristol-Myers Squibb's anti-CTLA-4 agent Yervoy and novel immune checkpoint inhibitors that target the anti-programmed cell death-1/programmed death-ligand-1 (PD-1/PD-L1) pathway-including Bristol-Myers Squibb/Ono Pharmaceutical's nivolumab, Merck & Co.'s pembrolizumab (MK-3475), Roche/Genentech/Chugai's MPDL-3280A and AstraZeneca/MedImmune's MEDI4736-will dominate the immunotherapy market and capture a staggering 85 percent market share in 2022.
Other key findings from the Pharmacor Immunotherapies advisory service:
Comments from Decision Resources Group Senior Business Insights Analyst Khurram Nawaz, M.Sc.:
About Decision Resources Group
Decision Resources Group offers best-in-class, high-value information and insights on critical issues within the healthcare industry. Clients rely on this analysis and data to make informed decisions. Find out more at www.DecisionResourcesGroup.com.
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact:
Decision Resources Group
©2012 PR Newswire. All Rights Reserved.